The design of probiotic targeted release tablets must be centered on the pathological mechanisms of intestinal diseases, achieving precise intervention through customized strain combinations. Different intestinal diseases (such as inflammatory bowel disease, irritable bowel syndrome, and antibiotic-associated diarrhea) have different pathogenic factors, involving mechanisms such as dysbiosis, mucosal barrier damage, immune abnormalities, or pathogen overgrowth. Therefore, strain selection must be based on functional complementarity, targeting specific pathological processes while also enhancing overall efficacy through synergistic effects. For example, for inflammatory bowel disease, strains with anti-inflammatory properties, such as *Lactobacillus reuteri*, should be prioritized, as it can inhibit pathogenic bacterial adhesion by secreting reuterin and simultaneously regulate immune cell activity, reducing the release of pro-inflammatory factors.
The customization of strain combinations must consider the complexity of the intestinal microenvironment. A healthy gut microbiota consists of hundreds of microorganisms, with symbiotic or antagonistic relationships existing between strains. The design of probiotic targeted release tablets must mimic the ecological structure of natural microbiota, selecting strain combinations capable of forming stable biofilms. For example, the combined use of Bifidobacteria and Lactobacillus can enhance adhesion to the intestinal mucosa, inhibiting the colonization of pathogenic bacteria through competitive exclusion. Furthermore, certain strains (such as Lactobacillus acidophilus) can produce organic acids, lowering the intestinal pH and creating a suitable environment for other beneficial bacteria, forming a positive ecological cycle. This synergistic effect of multiple strains is more consistent with intestinal physiology than that of a single strain, and can more comprehensively restore the balance of the gut microbiota.
Targeted release technology is a key aspect of customized design. Traditional probiotic preparations have low survival rates in the acidic and bile salt environments of the stomach, making it difficult to reach the lesion site. Through microencapsulation, multi-layer coating, or pH-responsive materials, precise release of strains into specific areas of the intestine can be achieved. For example, for colonic diseases, colon-targeting materials such as calcium pectin or polyacrylic acid resin can be used to release strains after the ileocecal junction, avoiding damage to the upper digestive tract. For small intestinal lesions, a time-delayed release system is required to ensure colonization of the small intestine. Targeted release technology not only improves strain survival rates but also reduces interference with non-lesion sites, lowering the risk of side effects.
Targeted bacterial strain combinations for different diseases require consideration of both functional mechanisms and clinical evidence. For example, antibiotic-associated diarrhea is often caused by the overgrowth of *Clostridium difficile*. In this case, strains that produce bacteriocins (such as *Pediococcus lactis*) should be selected to directly inhibit pathogen growth. Simultaneously, strains producing short-chain fatty acids (such as *Bifidobacterium longum*) can be used to repair the intestinal barrier and enhance mucosal immunity. For irritable bowel syndrome (IBS), the focus should be on strains that regulate intestinal motility (such as *Bifidobacterium animalis*), combined with *Lactobacillus plantarum*, which has analgesic effects, to relieve abdominal pain and bloating. This pathological mechanism-based strain selection significantly improves the specificity and effectiveness of treatment.
Strain safety is a prerequisite for customized design. Strains with drug resistance genes or potential pathogenicity must be excluded, and strains with extensive research and well-established safety profiles should be prioritized. For example, *Lactobacillus rhamnosus* GG strain and *Bifidobacterium animalis* BB-12 strain are recognized as safe and effective probiotics due to long-term clinical application validation. Furthermore, the genetic stability of the strains must also be assessed to avoid horizontal gene transfer in the gut, which could lead to safety risks. Rigorous screening and long-term safety monitoring ensure the biosafety of customized bacterial strain combinations.
Personalized needs are driving further segmentation of bacterial strain combinations. Different populations (such as children, the elderly, and pregnant women) have different gut microbiota, requiring adjustments to strain types and dosages. For example, children's gut microbiota is not yet fully mature, necessitating the selection of more tolerant strains (such as Lactobacillus acidophilus) and avoiding strains that may trigger allergies. The elderly, due to slowed intestinal motility, require an increased proportion of strains producing short-chain fatty acids to promote intestinal motility. Furthermore, for individuals with specific dietary habits (such as high-fat, high-sugar diets), bacterial strain combinations with metabolic regulatory functions can be designed to help improve gut health.
In the future, the design of probiotic targeted release tablets will rely more heavily on multi-omics technologies and artificial intelligence. Metagenomic analysis of gut microbiota characteristics, combined with metabolomics and immunomics data, can more accurately identify disease-related dysbiosis patterns. Artificial intelligence algorithms can simulate interactions between strains, predict optimal combination schemes, and shorten the development cycle. Meanwhile, 3D printing technology holds promise for enabling personalized customization of bacterial strain combinations, allowing for the on-site printing of targeted release tablets containing specific strains based on the patient's gut microbiota testing results. This precision medicine model will drive the transformation of probiotic targeted release tablets treatment from "universal" to "personalized," providing a more efficient solution for the management of intestinal diseases.
